HR-1768-119
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Budget, the Judiciary, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Frank Pallone (D-NJ)
What it does
This bill would reauthorize and expand a wide range of federal programs across three broad areas. In healthcare, it would extend Medicare and Medicaid eligibility and payment rates, expand telehealth coverage, require pharmacy benefit managers to pass 100% of drug rebates to health plans, and reauthorize programs for public health emergencies, substance use disorders, sickle cell disease, traumatic brain injuries, and care in underserved communities. In commerce, it would ban nonconsensual sharing of intimate images online, require disclosure of cameras and microphones on internet-connected devices, ban high-concentration sodium nitrite products, and mandate price transparency for concert tickets and hotel rooms. In the environment, it would fund community recycling, drinking water infrastructure, and diesel emission reduction, and allow year-round sale of E15 gasoline (10–15% ethanol blend).
Who benefits
Medicare beneficiaries who use telehealth services or see physicians and rural hospital providers. People aged 65 and over with medically improved disabilities who would newly qualify for Medicaid. Patients in underserved communities served by the National Health Service Corps. People with substance use disorders, traumatic brain injuries, or sickle cell disease. Group health plan enrollees who could receive more drug rebate savings. Victims of nonconsensual intimate image sharing (disproportionately women). Consumers of internet-connected devices who want clearer privacy disclosures. Concert-goers and hotel guests who would see fuller price disclosures upfront. Rural hospitals and physicians receiving extended payment increases. Ethanol producers and corn farmers who benefit from year-round E15 sales. Communities near diesel-heavy transportation corridors who would see reduced emissions. Children with rare diseases who may benefit from expanded FDA research authority.
Who is hurt
Pharmacy benefit managers (PBMs) who currently retain a portion of drug rebates and would be required to remit 100% to health plans. Manufacturers of high-concentration sodium nitrite products, which would be banned. Online platforms that may face compliance costs related to the nonconsensual image-sharing prohibition. Internet-connected device manufacturers facing new disclosure requirements. Ticket resellers and hotel booking platforms that may lose revenue from opaque pricing practices. Ethanol-free gasoline retailers and some auto manufacturers who have concerns about E15 compatibility with older vehicles. Taxpayers who would fund new and reauthorized grant programs. States and localities that may face administrative burdens implementing new federal requirements.
Supporters argue
Supporters argue that this bill addresses a broad set of well-documented gaps in healthcare access, consumer protection, and public health infrastructure. They contend that requiring PBMs to remit 100% of drug rebates directly reduces costs for health plan enrollees, and that extending Medicare telehealth coverage preserves access for rural and elderly patients who gained it during the COVID-19 pandemic. They further argue that provisions like the nonconsensual image-sharing ban and ticket price transparency fill clear regulatory voids where consumers currently have little federal protection, and that reauthorizing programs for substance use disorders and pandemic preparedness addresses ongoing public health crises with proven, existing frameworks.
Opponents argue
Opponents argue that bundling dozens of unrelated provisions into a single omnibus bill obscures accountability and prevents members of Congress from voting on each policy on its merits — a process concern that applies regardless of the individual provisions' worth. They contend that the PBM rebate mandate, while appealing in principle, may not lower consumer premiums if insurers absorb the savings, and that extending payment increases for Medicare providers adds to long-term federal spending without structural cost controls. They further argue that some provisions — such as year-round E15 sales — primarily benefit specific agricultural and fuel industries rather than the general public, raising questions about whether the bill's broad framing obscures targeted economic benefits for narrow interests.
Constitutional context
Congress's authority to regulate commerce, set conditions on federal spending programs like Medicare and Medicaid, and regulate internet-connected commerce rests on the Commerce Clause (Art. I, §8, cl. 3) and the Taxing and Spending Clause (Art. I, §8, cl. 1). NFIB v. Sebelius (2012) affirmed broad congressional authority to structure Medicare and Medicaid as spending programs with attached conditions, though it cautioned that Medicaid conditions cannot be so coercive as to leave states no real choice. Post-Loper Bright (2024), any agency rules implementing this bill's provisions would face independent judicial review rather than deferential review.
Checks and balances
Congress would expand executive branch authority across HHS, FDA, EPA, and FTC to implement new programs and mandates; oversight checks include congressional appropriations control, judicial review of agency rules under the post-Loper Bright independent judgment standard, and state-level implementation discretion for Medicaid provisions.
Historical precedent
Omnibus health reauthorization packages such as the Consolidated Appropriations Act of 2023 similarly bundled Medicare telehealth extensions, substance use disorder funding, and other health provisions into a single vehicle, establishing a pattern for this legislative approach.